The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus.

Borm AK, Klevesath MS, Borcea V, Kasperk C, Seibel MJ, Wahl P, Ziegler R, Naworth PP

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme1 Aug 1999Cited by 21 (Europe PMC)

PMID10494873DOI10.1055/s-2007-978777PepBankPUB-10494873

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, bone density did not change significantly during pramlintide therapy.
In plain wordsIn patients with type 1 diabetes, bone density did not change significantly during pramlintide treatment.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeBone density
Study
n = 23
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 ml four times per day · injection · 12 monthsAs given in this study (human).
Source sentences
Summary
None of the following parameters changed significantly: bone density, serum calcium, PTH, osteocalcin or pyridinium cross-links.
1 context sentence(design, population, supporting numbers)
Summary · context
23 patients with type 1 diabetes mellitus (age 45.2 +/- 10.3 years, duration of diabetes mellitus 20.7 +/- 9.8 years, 13 male, 10 female) injected themselves 0.1 ml pramlintide, a human amylin analogue, four times per day for a period of 12 months.
Report a problemFND-1049487301
02HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, serum calcium did not change significantly during pramlintide therapy.
In plain wordsIn patients with type 1 diabetes, blood calcium did not change significantly during pramlintide treatment.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeSerum calcium
Study
n = 23
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 ml four times per day · injection · 12 monthsAs given in this study (human).
Source sentences
Summary
None of the following parameters changed significantly: bone density, serum calcium, PTH, osteocalcin or pyridinium cross-links.
1 context sentence(design, population, supporting numbers)
Summary · context
23 patients with type 1 diabetes mellitus (age 45.2 +/- 10.3 years, duration of diabetes mellitus 20.7 +/- 9.8 years, 13 male, 10 female) injected themselves 0.1 ml pramlintide, a human amylin analogue, four times per day for a period of 12 months.
Report a problemFND-1049487302
03HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, PTH did not change significantly during pramlintide therapy.
In plain wordsIn patients with type 1 diabetes, PTH did not change significantly during pramlintide treatment.
Peptide
Pramlintide (Symlin)
Outcome
No significant changePTH
Study
n = 23
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 ml four times per day · injection · 12 monthsAs given in this study (human).
Source sentences
Summary
None of the following parameters changed significantly: bone density, serum calcium, PTH, osteocalcin or pyridinium cross-links.
1 context sentence(design, population, supporting numbers)
Summary · context
23 patients with type 1 diabetes mellitus (age 45.2 +/- 10.3 years, duration of diabetes mellitus 20.7 +/- 9.8 years, 13 male, 10 female) injected themselves 0.1 ml pramlintide, a human amylin analogue, four times per day for a period of 12 months.
Report a problemFND-1049487303
04HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, osteocalcin decreased nonsignificantly during pramlintide therapy.
In plain wordsIn patients with type 1 diabetes, osteocalcin decreased during pramlintide treatment, but the change was not significant.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeOsteocalcin
Study
n = 23
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 ml four times per day · injection · 12 monthsAs given in this study (human).
Measurements
Osteocalcin
7.205 ng/ml
before treatment
Osteocalcin
5.825 ng/ml
after treatment
Source sentences
Summary
Only osteocalcin decreased from 7.205 ng/ml to 5.825 ng/ml, but this change was not statistically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
23 patients with type 1 diabetes mellitus (age 45.2 +/- 10.3 years, duration of diabetes mellitus 20.7 +/- 9.8 years, 13 male, 10 female) injected themselves 0.1 ml pramlintide, a human amylin analogue, four times per day for a period of 12 months.
Report a problemFND-1049487304
05HumanNon-randomized trialEfficacy outcome
In patients with type 1 diabetes, pyridinium cross-links did not change significantly during pramlintide therapy.
In plain wordsIn patients with type 1 diabetes, pyridinium cross-links did not change significantly during pramlintide treatment.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeUrinary pyridinium cross-links
Study
n = 23
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 ml four times per day · injection · 12 monthsAs given in this study (human).
Source sentences
Summary
None of the following parameters changed significantly: bone density, serum calcium, PTH, osteocalcin or pyridinium cross-links.
1 context sentence(design, population, supporting numbers)
Summary · context
23 patients with type 1 diabetes mellitus (age 45.2 +/- 10.3 years, duration of diabetes mellitus 20.7 +/- 9.8 years, 13 male, 10 female) injected themselves 0.1 ml pramlintide, a human amylin analogue, four times per day for a period of 12 months.
Report a problemFND-1049487305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.